Abdulhadi Jfri1, David Nassim2, Elizabeth O'Brien1, Wayne Gulliver3, Georgios Nikolakis4,5, Christos C Zouboulis4,5. 1. Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada. 2. Faculty of Medicine, McGill University, Quebec, Quebec, Canada. 3. Division of Dermatology, Memorial University of Newfoundland, St John's, Newfoundland, Canada. 4. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany. 5. European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
Abstract
IMPORTANCE: Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. There are scarce data regarding the prevalence of HS. OBJECTIVE: To estimate overall HS prevalence. DATA SOURCES: This review and meta-regression analysis was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. The academic search included PubMed, Cochrane registry, ClinicalTrials.gov, and evidence by NHS UK and Trip databases from inception through May 2020. To analyze HS prevalence, only cross-sectional studies or baseline assessments of longitudinal cohorts using census-based surveys or probabilistic and nonprobabilistic epidemiologic methods were considered. The search terms were (prevalence OR incidence OR epidemiology) AND (hidradenitis suppurativa OR acne inversa OR Verneuil's disease). No language restriction was applied. STUDY SELECTION: Original investigations that reported HS prevalence were included. After exclusion criteria were applied, 17 studies qualified for qualitative analysis, but only 16 studies were quantitatively assessed. DATA EXTRACTION AND MEASURES: Two reviewers extracted data by age, diagnostic criteria, presence of any comorbidity, sample sizes, continent/location, sex, and other characteristics. Assessment of bias risk used the Joanna Briggs Institute Critical Appraisal Instrument for Studies Reporting Prevalence Data using random-effects models to synthesize available evidence. MAIN OUTCOMES AND MEASURES: Hidradenitis suppurativa prevalence (with 95% CI) among the overall population and among subgroups. Between-study heterogeneity was assessed (Cochran Q statistic) and quantified (I2 statistic). RESULTS: In 16 quantitatively assessed studies included, prevalence estimates were reported only from Western European and Scandinavian countries, the US, and Australia. Meta-analysis with random effects, after adjusting for publication bias in the prevalence estimates, revealed a 0.40% prevalence (95% CI, 0.26%-0.63%) for HS. Studies based on clinical samples revealed a higher pooled prevalence of HS (1.7%) than population-based studies (0.3%). CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-regression analysis may help facilitate policy formulation, channeling funding and guiding principles for better disease diagnosis using universal valid tools and management.
IMPORTANCE: Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. There are scarce data regarding the prevalence of HS. OBJECTIVE: To estimate overall HS prevalence. DATA SOURCES: This review and meta-regression analysis was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. The academic search included PubMed, Cochrane registry, ClinicalTrials.gov, and evidence by NHS UK and Trip databases from inception through May 2020. To analyze HS prevalence, only cross-sectional studies or baseline assessments of longitudinal cohorts using census-based surveys or probabilistic and nonprobabilistic epidemiologic methods were considered. The search terms were (prevalence OR incidence OR epidemiology) AND (hidradenitis suppurativa OR acne inversa OR Verneuil's disease). No language restriction was applied. STUDY SELECTION: Original investigations that reported HS prevalence were included. After exclusion criteria were applied, 17 studies qualified for qualitative analysis, but only 16 studies were quantitatively assessed. DATA EXTRACTION AND MEASURES: Two reviewers extracted data by age, diagnostic criteria, presence of any comorbidity, sample sizes, continent/location, sex, and other characteristics. Assessment of bias risk used the Joanna Briggs Institute Critical Appraisal Instrument for Studies Reporting Prevalence Data using random-effects models to synthesize available evidence. MAIN OUTCOMES AND MEASURES: Hidradenitis suppurativa prevalence (with 95% CI) among the overall population and among subgroups. Between-study heterogeneity was assessed (Cochran Q statistic) and quantified (I2 statistic). RESULTS: In 16 quantitatively assessed studies included, prevalence estimates were reported only from Western European and Scandinavian countries, the US, and Australia. Meta-analysis with random effects, after adjusting for publication bias in the prevalence estimates, revealed a 0.40% prevalence (95% CI, 0.26%-0.63%) for HS. Studies based on clinical samples revealed a higher pooled prevalence of HS (1.7%) than population-based studies (0.3%). CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-regression analysis may help facilitate policy formulation, channeling funding and guiding principles for better disease diagnosis using universal valid tools and management.
Authors: Ratnakar Shukla; Priyanka Karagaiah; Anant Patil; Katherine Farnbach; Alex G Ortega-Loayza; Thrasivoulos Tzellos; Jacek C Szepietowski; Mario Giulini; Hadrian Schepler; Stephan Grabbe; Mohamad Goldust Journal: J Clin Med Date: 2022-04-21 Impact factor: 4.964
Authors: Carlos André Dos Santos-Silva; Paola Maura Tricarico; Lívia Maria Batista Vilela; Ricardo Salas Roldan-Filho; Vinícius Costa Amador; Adamo Pio d'Adamo; Mireli de Santana Rêgo; Ana Maria Benko-Iseppon; Sergio Crovella Journal: Front Microbiol Date: 2021-12-13 Impact factor: 5.640
Authors: Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis Journal: Int J Environ Res Public Health Date: 2021-06-06 Impact factor: 3.390
Authors: Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee Journal: Drugs Date: 2021-07-20 Impact factor: 9.546